BRITAIN'S National Institute
for Health and Care Excellence
(NICE) has recommended the
PCSK9 inhibitors alirocumab and
evolocumab for patients with
primary hypercholesterolaemia
or mixed dyslipidaemia that is not
controlled with statins.
The update is part of final draft
guidance based on manufacturers
providing the drugs at discounted
prices.The above article was sent to subscribers in Pharmacy Daily's issue from 10 May 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 10 May 16
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.